Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes by Mullen, KA et al.
Effectiveness of a hospital-initiated smoking
cessation programme: 2-year health and healthcare
outcomes
Kerri A Mullen,1 Douglas G Manuel,2 Steven J Hawken,2 Andrew L Pipe,1
Douglas Coyle,3 Laura A Hobler,1 Jaime Younger,2 George A Wells,1 Robert D Reid1
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
tobaccocontrol-2015-052728).






3University of Ottawa, Ottawa,
Ontario, Canada
Correspondence to
Dr Kerri Anne Mullen, 40
Ruskin Street, H2353, Ottawa,
Ontario, Canada K1Y 4W7;
kmullen@ottawaheart.ca
Received 25 September 2015
Accepted 20 April 2016
To cite: Mullen KA,
Manuel DG, Hawken SJ,
et al. Tob Control Published





Background Tobacco-related illnesses are leading
causes of death and healthcare use. Our objective was
to determine whether implementation of a hospital-
initiated smoking cessation intervention would reduce
mortality and downstream healthcare usage.
Methods A 2-group effectiveness study was completed
comparing patients who received the ‘Ottawa Model’ for
Smoking Cessation intervention (n=726) to usual care
controls (n=641). Participants were current smokers,
>17 years old, and recruited during admission to 1 of
14 participating hospitals in Ontario, Canada. Baseline
data were linked to healthcare administrative data.
Competing-risks regression analysis was used to compare
outcomes between groups.
Results The intervention group experienced
signiﬁcantly lower rates of all-cause readmissions,
smoking-related readmissions, and all-cause emergency
department (ED) visits at all time points. The largest
absolute risk reductions (ARR) were observed for all-
cause readmissions at 30 days (13.3% vs 7.1%; ARR,
6.1% (2.9% to 9.3%); p<0.001), 1 year (38.4% vs
26.7%; ARR, 11.7% (6.7% to 16.6%); p<0.001), and
2 years (45.2% vs 33.6%; ARR, 11.6% (6.5% to
16.8%); p<0.001). The greatest reduction in risk of all-
cause ED visits was at 30 days (20.9% vs 16.4%; ARR,
4.5% (0.4% to 8.7%); p=0.03). Reduction in mortality
was not evident at 30 days, but signiﬁcant reductions
were observed by year 1 (11.4% vs 5.4%; ARR 6.0%
(3.1% to 9.0%); p<0.001) and year 2 (15.1% vs 7.9%;
ARR, 7.3% (3.9% to 10.7%); p<0.001).
Conclusions Considering the relatively low cost,
greater adoption of hospital-initiated tobacco cessation
interventions should be considered to improve patient
outcomes and decrease subsequent healthcare usage.
INTRODUCTION
Tobacco smoking remains the leading cause of pre-
mature death worldwide.1 It is unparalleled in pro-
ducing early and preventable disease, disability and
death, particularly related to cardiovascular and
respiratory diseases and cancer.2 The magnitude of
the excess morbidity, mortality and healthcare
usage caused by tobacco addiction is immense.2 3
Sadly, smoking remains a widespread condition that
‘presents such a mixture of lethality, prevalence and
neglect despite effective and readily available
interventions’.4
In every jurisdiction, healthcare systems are
experiencing the growing burden of chronic dis-
eases and are under pressure to reduce ‘avoidable’
hospital readmissions.5 6 For example, the English
Department of Health introduced a policy in 2011
restricting payments of certain emergency readmis-
sions that occur within 30 days of an initial hospital
discharge.6 In the USA, the Hospital Readmissions
Reductions Program was introduced as part of the
Affordable Care Act; consequently, thousands of
hospitals will have Medicare payments deducted by
up to 3% in 2015 if patients with certain condi-
tions (eg, myocardial infarction, heart failure,
chronic obstructive pulmonary disease) return to
hospital within 30 days of discharge.7
In Canada, smokers average twice as many hos-
pital days as never-daily smokers.8 Given the
number of smokers admitted to hospitals, the rele-
vance of smoking to their illness, the realities of
nicotine addiction, and the challenges of with-
drawal, hospitalisation presents a signiﬁcant and
strategic opportunity to deliver cessation interven-
tions.9–11 There is abundant evidence that hospital-
based interventions are highly effective at helping
patients quit, particularly when pharmacotherapy is
provided in association with counselling and post-
discharge support (risk ratio (RR), 1.37 (1.27 to
1.48); 25 trials).12 The ‘Ottawa Model’ for
Smoking Cessation (OMSC) is a systematic
approach to tobacco dependence treatment deliv-
ered within healthcare settings that has been inte-
grated within over 120 hospitals across Canada. It
involves: identifying and documenting the smoking
status of all patients; providing brief counselling
and inhospital pharmacotherapy to smokers; and,
offering follow-up support posthospitalisation.13 14
The model has been found to improve long-term
cessation by an absolute 11% (from 18% to 29%;
OR, 1.71 (1.11 to 2.64); p=0.02) among general
hospital patients.13
Evidence of the health beneﬁts of smoking cessa-
tion is overwhelming, particularly for younger
people without existing disease, but also for higher
risk individuals with smoking-related illnesses.2 15–17
A small number of investigations have assessed the
health and healthcare consequences of cessation
interventions delivered in hospital. They have relied
on self-report, assessed only condition-speciﬁc out-
comes, or used mathematical modelling to obtain
outcomes.18–21
Our investigation assessed the direct effects of a
hospital-initiated smoking cessation intervention
(the OMSC) on mortality, rehospitalisation, emer-
gency department (ED) use, and physician visits
using healthcare administrative data. We hypothe-
sised that, compared to controls, OMSC interven-
tion patients would experience reduced healthcare
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We completed a two-group effectiveness study comparing
patients who received the OMSC intervention with preimple-
mentation controls (approved by the Ottawa Hospital Research
Ethics Board: Protocol#:2011889-01). Our study was con-
ducted in Ontario, Canada, and expanded on a previous investi-
gation examining smoking cessation effectiveness.13 Participants
were recruited from one of 14 hospitals that, at baseline, did
not have a formal cessation intervention in place but were plan-
ning to implement the OMSC. Hospital characteristics are sum-
marised in table 1.
Participants
Patients were eligible if they: were >17 years of age; smoked ≥1
cigarette per day in the 6 months prior to their index hospital-
isation; lived in Ontario; and qualiﬁed for the Ontario Health
Insurance Plan (OHIP) throughout the study. A total of 1649
patients were eligible; 741 smokers who received usual care and
908 smokers who received the OMSC (table 1).
Control group
Prior to implementing the OMSC, a consecutive sample of
patients admitted to each participating hospital was screened for
tobacco use by using a standardised tool. Hospitals were provid-
ing ‘usual care’ (typically the availability of self-help brochures)
throughout this period.
Intervention group
Following control group recruitment, participating hospitals
implemented the OMSC programme which involves changes in
policies and procedures such that a new standard of care is
introduced.13 14 Once implemented, regardless of long-term
intentions to quit, all smokers admitted to participating hospi-
tals received the following intervention components: (1) desig-
nated healthcare staff completed a bedside consultation using a
standardised form. The form documented smoking history and
guided staff in recommending cessation pharmacotherapies, pro-
viding brief counselling, and enrolling patients in follow-up; (2)
pharmacotherapies were ordered, as appropriate, through hos-
pital pharmacies using preprinted order forms. Printed recom-
mendations for continuing pharmacotherapies postdischarge
were provided; (3) smokers who agreed were registered in an
automated telephone follow-up system (TelASK Technologies
Inc, Ottawa, Canada) at discharge and were contacted eight
times over 6 months.22 Those who indicated they had relapsed
to smoking or had low conﬁdence were ﬂagged by the system
and called by smoking cessation nurse-specialists who provided
counselling. After the OMSC had been in place for at least
2 months, a consecutive sample of patients who had received
the OMSC was recruited using the same process and screening
tool as for control group recruitment.
Covariates, outcomes and data sources
Age, sex, smoking status (yes/no to ‘have you smoked any form
of tobacco in the past 6 months?’), and average number of cigar-
ettes per day were collected during patient recruitment.
Additional covariates thought to potentially confound or inter-
act with our main outcomes were gathered through data linkage
and are summarised in online supplementary table S1.
Participants were individually linked to administrative data bases
at the Institute for Clinical Evaluative Sciences (ICES). ICES is
an independent, non-proﬁt research organisation and ‘pre-
scribed entity’ under Ontario’s Personal Health Information
Protection Act.23
Outcomes were assessed 30 days, 1 year, and 2 years follow-
ing the index hospitalisation. Our primary outcomes were all-
cause mortality and all-cause hospital readmission. Secondary
outcomes included: smoking-related readmission; all-cause and
smoking-related ED visits; and all-cause and smoking-related
physician visits (specialist and general practitioner). Mortality
data were acquired from the Registered Persons Database;24 hos-
pital readmission data from the Canadian Institutes of Health
Information (CIHI)—Discharge Abstract Database;25 ED visit
data through CIHI’s National Ambulatory Care Reporting
System;26 and physician visit data through the OHIP database.
We created a variable identifying whether or not events were
smoking-related based on conditions in ‘The Health
Consequences of Smoking—50 Years of Progress: A Report of
the Surgeon General’.2 27
Statistical methods
Baseline characteristics were compared using t tests and χ2 tests,
as appropriate. For our principal analyses, competing-risks
regression was used.28 Competing-risks regression compares the
cumulative incidence of an event (ie, rehospitalisation, ED visit,
physician visit) between two groups over a period of time in the
presence of a competing risk (ie, death). Participants remained
under observation until death or the end of the study, and those
who experienced neither an event of interest nor the competing
event were right-censored at the end of each analysis period.
The primary independent variable in our models was group
(control or intervention). Adjusted models included all covari-
ates listed in table 2, which were treated as ﬁxed at baseline.
Hospital (n=14) was used as the clustering variable. We com-
pleted a power calculation using PASS Software 12.0.3 (NCSS,
LLC). Using a competing-risks model and a sample of 1400
(700 control and 700 intervention), we had >90% power to
detect a HR as modest as 0.56, estimated from a published ran-
domised control trial.18 An α level of 0.05 and two tails were
used for all tests of signiﬁcance. Interval estimates were based
on 95% CIs. Analyses were carried out using SAS V.9.3 (Cary,
North Carolina, USA).
Bias
Several strategies were employed to ensure transparency and to
address potential biases. First, an evaluation committee, includ-
ing all study investigators and a third party chair, was formed
prior to study commencement. The committee documented all
real and potential conﬂicts of interest and approved the study
design, outcomes, covariates, analysis plan, and dissemination
plan. Once analyses were completed, the committee reviewed
the study ﬁndings to verify that all plans had been followed. To
reduce potential analyst bias, an initial, blinded analysis of the
data was completed. A ‘blinded’ test data set was created by an
analyst (Analyst 1) who removed identifying information (eg,
dates, group assignments), randomly added observations to the
smallest group in order that groups be identical in size, and ran-
domly assigned new group numbers. The study’s primary inves-
tigator (Analyst 2) and an arm’s length analyst (Analyst 3) used
this test data set to independently complete blinded analyses of
the study’s main outcomes. Results of their independent ana-
lyses were reviewed by Analyst 1, and any necessary corrections
were made. Once consensus was reached (ie, statistical coding
and ﬁnal outputs matched), the primary analyses were repeated
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independently by Analysts 2 and 3 using the actual study data
set to obtain ﬁnal results.
The consecutive nature in which patients were recruited to
the study was intended to limit selection bias, and several
planned sensitivity analyses were completed to investigate
potential sources of bias within the data.
Sensitivity analyses
We examined consistency of our results for 2-year mortality and
all-cause readmissions by stratifying each covariate and assessing
stratum-speciﬁc HRs. To consider the speciﬁcity of our results
(ie, whether between-group differences were speciﬁc to hospita-
lised smokers and could be attributed to intervention exposure,
rather than secular temporal trends unrelated to the interven-
tion), we compared the 2-year probabilities of all-cause mortal-
ity and readmission between two consecutive samples of
non-smoking patients who were recruited alongside the control
and intervention smoker-patients. The intervention could not
conceivably have inﬂuenced outcomes in the non-smokers, so
any observed trends would suggest that external factors were at
play. Further, we assessed whether quitting smoking improved
outcomes on a subsample of smokers in both groups who con-
sented to a 6-month follow-up call after their index hospitalisa-
tion. These participants responded yes or no to: ‘Have you
smoked any form of tobacco in the past 6 months?’. We com-
bined the quitters and continued smokers from each group and
continuous smoking abstinence was the main independent vari-
able in a competing-risks regression analysis.
RESULTS
Participants
Of the 1649 eligible smokers screened, our ﬁnal study dataset
included 641 control (86.5% of smokers screened) and 726
intervention smokers (80.0% of smokers screened). A total of
282 smokers were excluded; 247 were unable to be linked (ie,
unique healthcare number, name, or date of birth could not be
matched); and, 35 were ineligible for OHIP for a period of time
during the study. Table 2 presents baseline participant character-
istics. The intervention group had a higher history of AMI
(22.2% vs 12.5%); controls had a higher history of cancer
(11.5% vs 6.2%). In all other respects, the groups were similar.
Primary outcomes
Figure 1 displays the results of our competing-risks regression
analyses. The intervention group experienced signiﬁcant reduc-
tions in the probabilities of all-cause readmissions,
smoking-related readmissions, and all-cause ED visits at all time
Table 1 Description of participating hospitals during patient recruitment periods
Control group recruitment Intervention group recruitment



















1 M, TC, T 3/6 January/2005 3 204 47 July/2006 6 770 177
2 S, G 1/1 January/2006 2 83 19 February/2007 2 60 9
3 L, TC, T 2/14 January/2006 2 332 61 March/2007 0.8 149 31
4 S, G 2/4 January/2006 5 164 41 May/2007 1 147 40
5 S, G 5/5 February/2006 1 182 46 October/2007 2 161 37
6 L, TC, T 5/15 March/2006 2 481 114 May/2007 2 352 75
7 L, TC, T 4/15 May/2006 0.3 504 98 September/2008 0.8 852 129
8 S, G 1/1 June/2006 2 57 9 October/2007 8 122 28
9 M, G 6/6 June/2006 3 726 128 February/2007 1 856 129
10 S, G 2/3 June/2006 1 121 20 May/2007 2 191 44
11 S, G 1/1 August/2006 1 104 29 November/2007 1 102 29
12 S, G 1/1 March/2007 1 26 4 April/2008 6 150 18
13 L, TC, T 5/14 March/2007 2 267 62 January/2008 4 357 82
14 M, G 3/4 September/2007 2 317 63 May/2009 1 348 80
3568 741 4617 908
Units, Number of participating hospital units/number of total possible hospital units; Recruitment length, number of months during which the consecutive screening of patients took
place.
G, general; L, large; M, medium; S, small; T, teaching; TC, tertiary care.





Age, mean (SD) 52.1 (16.9) 52.3 (14.8) 0.86
Male sex, n (%) 295 (46.0) 367 (50.5) 0.09
Low-SES (lowest two income
quintiles), n (%)
321 (50.0) 357 (49.1) 0.68
Smokes >20 cpd, n (%) 205 (32.0) 235 (32.4) 0.28
Rurality (RIO) score, mean (SD) 17.3 (21.2) 16.2 (22.8) 0.37
High overall morbidity (RUB
score >3), n (%)
439 (68.5) 531 (73.1) 0.08
History of AMI, n (%) 80 (12.5) 161 (22.2) <0.001
Asthma, n (%) 123 (19.2) 125 (17.2) 0.35
History of recent cancer, n (%) 74 (11.5) 45 (6.2) <0.001
CHF, n (%) 70 (10.9) 79 (10.9) 0.98
COPD, n (%) 191 (29.8) 213 (29.3) 0.85
Diabetes, n (%) 127 (19.8) 138 (19.0) 0.71
Hypertension, n (%) 266 (41.5) 306 (42.2) 0.81
History of mental illness, n (%) 59 (9.2) 90 (12.4) 0.06
History of stroke or TIA, n (%) 59 (9.2) 48 (6.6) 0.07
AMI, acute myocardial infarction; CHF, heart failure; COPD, chronic obstructive
pulmonary disease; CPD, cigarettes per day; N, number; RIO, rurality index of ontario;
RUB, resource utilisation band; SES, socioeconomic status; TIA, transient ischemic
attack.
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points. The largest absolute risk reductions (ARR) were
observed for all-cause readmissions at 30 days (13.3% vs 7.1%;
ARR, 6.1% (2.9% to 9.3%); p<0.001), 1 year (38.4% vs
26.7%; ARR, 11.7% (6.7% to 16.6%); p<0.001), and 2 years
(45.2% vs 33.6%; ARR, 11.6% (6.5% to 16.8%); p<0.001).
The greatest reduction in risk of all-cause ED visits was at
30 days (20.9% vs 16.4%; ARR, 4.5% (0.4% to 8.7%);
p=0.03). Reduction in mortality was not evident at 30 days, but
signiﬁcant reductions were observed by year 1 (11.4% vs 5.4%;
ARR 6.0% (3.1% to 9.0%); p<0.001) and year 2 (15.1% vs
7.9%; ARR, 7.3% (3.9% to 10.7%); p<0.001). Figure 2 dis-
plays the 2-year cumulative incidence curves for the primary
outcomes.
Sensitivity analyses
Most stratum-speciﬁc results were consistent with our primary
results, with the following exceptions. For 2-year all-cause mor-
tality, the intervention had an impact on patients with no
history of mental illness (HR; 0.68 (0.58 to 0.79); p<0.001)
and those living in urban areas (HR, 0.36 (0.21 to 0.59);
p<0.001); however, not on those with mental illness (HR, 1.31
(0.40 to 5.01); p=0.69) or in rural areas (HR, 1.10 (0.47 to
2.68); p=0.79). For 2-year all-cause readmissions, effects dif-
fered among the following subgroups: patients with lower socio-
economic status (SES) (HR, 0.68 (0.57 to 0.80); p<0.001)
compared with higher SES (HR, 1.01 (0.78 to 1.31); p=0.96);
patients with CHF (HR, 1.07 (0.78 to 1.47); p=0.42) com-
pared with patients without (HR, 0.68 (0.58 to 0.80);
p<0.001); and, patients with mental illness (HR, 1.41 (0.96 to
2.11); p=0.005) compared with those without (HR, 0.68 (0.58
to 0.79); p<0.001).
Twelve hospitals contributed non-smoker data (non-smoker
characteristics are summarised in online supplementary table
S2). The non-smokers were, on average, 12 years older than the
smokers and had higher SES and overall morbidity. We observed
no differences in 2-year mortality (HR, 1.14 (1.21 to 1.61);
p=0.12), 2-year all-cause rehospitalisation (HR, 0.99 (0.92 to
1.08); p=0.97), or 2-year smoking-related rehospitalisation
(HR, 1.08 (0.98 to 1.19); p=0.64) between ‘control’ and ‘inter-
vention’ non-smokers.
In the subsample of smokers for whom we had 6-month
smoking abstinence data, 45 of 221 (20.4%) control patients
had quit compared to 90 of 256 (35.2%) intervention patients
(χ2 12.8; p<0.001). Over 2 years, those who had been smoke-
free at 6 months were less likely to be rehospitalised than those
who continued to smoke (HR, 0.78 (0.58 to 1.03); p=0.04),
and 47% less likely to die (HR, 0.53 (0.32 to 0.83); p=0.07).
Post hoc analysis
We explored whether the group difference in cancer history
explained the observed difference in mortality. Thirty-four of
74 (45.9%) smokers with cancer in the control group had died
by year 2, compared to 20 of 45 (44.4%) in the intervention
group; there was no signiﬁcant difference in 2-year probability
of death between control and intervention patients with cancer
(HR, 0.84 (0.43 to 1.56); p=0.51).
DISCUSSION
Our objectives were to determine the effects of the OMSC on
mortality and healthcare usage in a real-world effectiveness
study with usual care controls. We observed signiﬁcant reduc-
tions in 30-day, 1-year and 2-year healthcare usage, particularly
for costly acute-care services, following OMSC implementation
at 14 Ontario hospitals. Intervention patients experienced con-
siderable reductions in mortality risk at 1-year and 2-year
follow-ups.
Figure 1 30-day, 1-year and 2-year outcomes of competing-risk regression for smokers receiving either OMSC (intervention, n=726) or usual care
(control, n=641). AR, attributable risk; ED, emergency department; GP, general practitioner; NNT/H, number needed to treat/harm (negative values
represent number needed to harm); Phys, physician; rel, related. A, adjusted for baseline covariates: age, sex, income, number of cigarettes smoked
per day, community size, resource usage prior to index event, and history of: acute myocardial infarction, asthma, chronic obstructive pulmonary
disease, heart failure, diabetes, hypertension, mental illness, stroke/transient ischemic attack.
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Our main ﬁndings are consistent with previous studies that
have found smoking cessation to reduce morbidity and mortality
in high-risk and general populations of smokers.15–18 29 We are
aware of two studies that examined rates of hospital readmission
following a hospital-based cessation intervention. The ﬁrst
observed a 44% relative risk reduction in hospital readmissions
(16–63%, p=0.007) among smokers with acute cardiovascular
conditions who were randomised to receive an intensive
hospital-initiated intervention, compared to smokers in the
control group.18 Our 2-year absolute risk reduction in mortality
of 7.2% was similar to theirs of 9.2%. The second assessed
rates of psychiatric readmission following an index hospitalisa-
tion.20 Smoker-patients who received a computerised cessation
intervention and offer of 6 months of nicotine replacement
therapy were less likely than controls to be rehospitalised for
psychiatric conditions over 18 months (OR, 1.92 (1.06 to 3.49);
p=0.04). The above studies relied on self-reported readmission
data. To our knowledge, our study is the ﬁrst to compare health
outcomes of smokers who received an inhospital cessation inter-
vention to controls by directly linking to healthcare administra-
tive data.
Our study found that attenuation of the risk of death and of
hospital readmission improved during the 2-year study period;
whereas, the impact on ED-visits decreased. Despite the
important short-term effects of smoking abstinence, many of
the effects of quitting on morbidity and mortality are observed
after many years.17 30 Preventing relapse is, therefore, an
important component of any cessation programme. Future
hospital-initiated programmes might be enhanced by usefully
examining ‘opt-out’ approaches to follow-up support,31 as well
as relapse recovery and re-engagement strategies to support
long-term abstinence.32
Our results were consistent for the majority of subgroups.
The OMSC intervention was highly effective among low-SES
patients. This is in contrast with a review which found that most
cessation interventions do not reach, or are ineffective in,
low-SES populations—populations that tend to have higher
smoking rates and use a greater proportion of healthcare
resources.33 Two recent randomised controlled trials (RCTs)
have reported ﬁndings similar to ours. The ﬁrst examined a pro-
active intervention delivered in primary care settings that
doubled abstinence rates among low-SES smokers.34 The second
evaluated an intervention that offered brief motivational coun-
selling, 6 weeks of cost-free nicotine replacement therapy, and
referral to a state quit-line to low-income smokers seen in an
ED. It found that biochemically conﬁrmed, 3-month smoking
abstinence was an absolute 7.3% (12.2% vs 4.9%) higher
among intervention group participants.35
Figure 2 Cumulative incidence of mortality (Part A) and all-cause rehospitalisation (Part B) from index hospitalisation to 2-year follow-up in the
control (n=641) and intervention (n=726) groups.
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We did not observe differences in primary outcomes between
the ‘control’ and ‘intervention’ non-smokers suggesting that our
results are speciﬁc to hospitalised smokers who received the
intervention. Patients who had quit smoking experienced similar
reductions in rehospitalisation and mortality as those in the
intervention group, further supporting our hypotheses.
The results of our descriptive statistics revealed interesting dif-
ferences between smokers and non-smokers. Smokers were hos-
pitalised 12 years earlier than non-smokers, likely due to earlier
occurrence of smoking-related illnesses. Half the smokers in our
study were in the lowest two income quintiles, and 11% had a
history of mental illness. By contrast, over 60% of non-smokers
were in the top three income quintiles, and only 5% had a
history of mental illness, conﬁrming previously identiﬁed corre-
lations and health disparities between and among smokers, indi-
viduals with low-SES, and those with mental illness.33 36 37
Limitations
Our study included data speciﬁc to healthcare usage in Ontario;
we did not have data concerning services that patients may have
received in other jurisdictions, which may have resulted in an
underestimate of total healthcare usage over the follow-up
period. While not an RCT, we are conﬁdent in the quality of
our results given the inclusion of a preimplementation control
group, and that data were collected during a high-quality
tobacco-use evaluation involving a consecutive sample of
patients from each hospital. We did not have information about
speciﬁc usage of cessation medications, nor did we have infor-
mation related to exposure to other cessation services patients
may have experienced. Smoking abstinence data were only avail-
able on a subsample of patients. We had no information about
second-hand smoke exposure, nor did we have smoking history
information for the non-smokers. Other interventions may
differ from the OMSC in intensity and efﬁcacy. Extrapolation of
our results to other settings should consider these limitations.
CONCLUSIONS
Signiﬁcant early and sustained reductions in mortality, rehospita-
lisation and ED use were observed following implementation of
the OMSC hospital-based intervention. This study supports the
case for broader adoption of systematic cessation interventions
within hospitals that advise patients about quitting, initiate ces-
sation pharmacotherapies, and attach patients to follow-up
support posthospitalisation. Such strategies, we would argue,
will reduce subsequent healthcare consumption and the burden
of the ‘revolving door’ patient; but, most importantly, distinctly
enhance the well-being of patients.
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